At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
PF-04449913drug
Likely dose
PF-04449913 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of PF-04449913 for the Treatment of Acute Myeloid Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse
In Brief
A Phase 2 clinical trial evaluating PF-04449913 for Adult Acute Myeloid Leukemia in Remission and Recurrent Adult Acute Myeloid Leukemia. Completed, enrolled 31 participants across 2 sites.
Detailed Summary
This phase II trial will test whether the Hedgehog signaling pathway inhibitor PF-04449913 can decrease disease relapse in high-risk patients with acute myeloid leukemia after donor stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsThe Leukemia and Lymphoma Society
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartApr 2013
Primary CompletionMay 2019
Study CompletionFeb 2020
TodayJul 2026
First PostedApr 26, 2013
Enrollment StartApr 29, 2013
Primary CompletionMay 8, 2019
Study CompletionFeb 4, 2020
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 13.2 years ago
Interventions
PF-04449913drug
100mg given orally